top of page


News


Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to...
Oct 12, 2021


Alpha Tau & Healthcare Capital Corp. to Combine and Create A $1-Billion Publicly Traded Company
Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Treatment of Solid...
Jul 11, 2021


First Alpha DaRT Patient Treated in the US as Part of Pilot Multicenter Skin Cancer Trial
Jerusalem, Israel, July 6, 2021 - Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRTTM,...
Jul 8, 2021


Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™
JERUSALEM, June 8, 2021 /PRNewswire/ -- Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT,TM...
Jun 13, 2021


Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
Tel Aviv, Israel, June 4, 2020 - Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased...
Jun 4, 2020
bottom of page








